Estrogenic activity of glabridin and glabrene from licorice roots on human osteoblasts and prepubertal rat skeletal tissues.
Data from both in vivo and in vitro experiments demonstrated that glabridin and glabrene are similar to estradiol-17beta in their stimulation of the specific activity of creatine kinase, although at higher concentrations, but differ in their extent of action and interaction with other drugs. In pre-menopausal human bone cells, the response to estradiol-17beta and glabridin (at higher concentration) was higher than in post-menopausal cells; whereas, glabrene (at higher concentration) was more effective in post-menopausal cells. At both ages, the response to estradiol-17beta and glabridin was enhanced by pretreatment with the less-calcemic Vitamin D analog CB 1093 (CB) and the demonstrably non-calcemic analog JK 1624 F(2)-2 (JKF). The response to glabrene was reduced by this pretreatment. Both glabridin and glabrene stimulated creatine kinase specific activity in diaphyseal bone and epiphyseal cartilage of prepubertal female rats. Daily feeding (3-14 days) of prepubertal female rats with glabridin, estradiol-17beta or their combination, also stimulated creatine kinase specific activity. Glabridine, similarly to estradiol-17beta, also stimulated creatine kinase specific activity in ovariectomized female rats. Raloxifene, in combination with glabridin or estradiol-17beta, demonstrated the phenomenon of mutual annihilation of stimulation of creatine kinase specific activity in both epiphysis and diaphysis. Glabrene activity was not inhibited by raloxifene. Therefore, glabridin shows greater similarity to estradiol-17beta and thus greater potential, with or without Vitamin D, to modulate bone disorders in post-menopausal women.
Somjen
Dalia
D
Institute of Endocrinology, Metabolism and Hypertension, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 64239, Israel. dalias@tasmc.health.gov.il
Katzburg
Sara
S
Vaya
Jacob
J
Kaye
Alvin M
AM
Hendel
David
D
Posner
Gary H
GH
Tamir
Snait
S
D000818:Animals; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000494:pharmacology; D003402:Creatine Kinase / Q000378:metabolism*; D004338:Drug Combinations; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D006035:Glycyrrhiza / Q000737:chemistry*; D006132:Growth Plate / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology*; D010006:Osteoblasts / Q000187:drug effects* / Q000201:enzymology; D010052:Ovariectomy; D010636:Phenols / Q000494:pharmacology*; D018517:Plant Roots / Q000737:chemistry*; D017698:Postmenopause; D017697:Premenopause; D020849:Raloxifene Hydrochloride / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D014807:Vitamin D / Q000031:analogs & derivatives / Q000494:pharmacology
C103436:CB 1093; D004338:Drug Combinations; D004967:Estrogens; D007529:Isoflavones; D010636:Phenols; D014807:Vitamin D; D020849:Raloxifene Hydrochloride; C439678:glabrene; D003402:Creatine Kinase; D002117:Calcitriol; C107601:glabridin